Solid Tumor Testing

Our clinical expertise in diagnosing solid tumors is unsurpassed in the testing industry. With over 20 years of experience in this field and a world-class staff of academic and community-trained physicians and scientists, we can work with you to properly diagnose your patients’ specimens.

• Breast Cancer Analysis More >
• Colorectal Cancer Analysis More >
• Complex Tumor Analysis More >

Breast Cancer Analysis

We are a national leader in breast cancer predictive and diagnostic analysis, providing critical information on over 20% of all newly diagnosed breast cancer cases in the United States.

Take a Look at Our Numbers

20%	We see over 20% of all newly diagnosed breast cancer cases in the U.S.
175,000	We have studied more than 175,000 samples for HER-2 analysis.
6,556	We have studied more than 6,556 breast cancers, comparing IHC with FISH.
9	We have nine full-time surgical pathologists on staff with extensive experience in breast cancer.
25	We have over 25 years of breast cancer diagnostic experience.

Prognostic & Predictive Markers

• ER
• MIB-1/Ki-67
• PR
• p53
• HER2 (IHC & FISH)
• EGFR

DNA Analysis

• S-phase and DNA index/ploidy by flow cytometry

Micrometastases Detection

• Lymph node by lHC
• Bone marrow by ICC

Chemotherapeutic Drug Resistance

• DRA^TM (Drug Resistance Assay)

Hormone Receptors

Estrogen and progesterone steroid receptors serve as receptors for growth factors stimulating tumor proliferation. The current guidelines for the use of these markers in the clinical setting are to:

• Predict response to therapy of metastatic disease
• Predict response to adjuvant therapy

Markers of Cell Proliferation

The combined use of MIB-1/Ki-67 and S-phase offers a precise interpretation of cell proliferation enabling S-phase to be compared with Ki-67, which detects all phases of the cycle except G0/.

HER2 Amplification/Expression

HER2 overexpression is associated with a varied positive response to the humanized monoclonal antibody Herceptin^® in patients that have failed standard chemotherapy treatment. Amplification of the HER2 gene is associated with rapid proliferation, short disease-free survival and poor overall survival in both node-negative and node-positive ductal breast cancers. HER2 amplification also predicts resistance to standard chemotherapy and response to anthracycline agents (adriamycin) in high dose chemotherapy. Recent studies also show a strong association of HER2 gene amplification measured by FISH with response to Herceptin therapy in patients with advanced breast carcinoma.

Colorectal Cancer Analysis

The application of biomarkers in colorectal cancer has been extensively studied both biologically and clinically. This application is of strong prognostic and predictive (therapeutic) value for patient outcome.

Prognostic & Therapeutic Markers

• p27
• Microsatellite instability fragment analysis by PCR
• p53
• hMLH-1/hMSH-2/hMSH-6/PMS2
• Thymidylate synthase (TS)
• EGFR

DNA Analysis

• S-phase and DNA index/ploidy by flow cytometry
• DNA index/ploidy and proliferation by image analysis

Micrometastases Detection

• Lymph node by IHC

Complex Tumor Analysis

For diagnostically difficult tumors, clients may choose from a list of profiles or provide relevant patient history, including provisional or differential diagnoses, and leave the rest to us.

Our pathologists will select the most appropriate combination of tests from our library of over 200 antibodies to evaluate the biological characteristics of the tumor and provide you with an accurate interpretation or diagnosis.

For your convenience, we have posted a PDF of our informative physician brochure on this page.

		Search by Test Name or Condition:
		Search by Test Name:
		Select a test .... ABL Kinase Domain Mutation Analysis in CML Alliance RQ-PCR Analysis AML1/ETO by PCR – t(8;21) by RT-PCR B-Cell Gene Rearrangements by PCR BCR-ABL - t(9;22) by RT-PCR (Quantitative) Bone Marrow - Peripheral Blood Smear Interpretation Bone Marrow - Smear Interpretation Bone Marrow Morphology - Complete Studies Bone Marrow Morphology - Cytochemistry Breast Cancer - DNA Ploidy/S-Phase Analysis by Flow Cytometry Breast Cancer - Individual Markers by IHC Breast Cancer - Interactive Quantitative Cellular Analysis (i QCA) Breast Cancer - Profiles Chromosome Analysis - Blood Chromosome Analysis - Bone Marrow Chromosome Analysis - Solid Tumor CLL-MRD (Minimial Residual Disease) by Flow Cytometry Colorectal Cancer - DNA Ploidy/S-Phase Analysis by Flow Cytometry Colorectal Cancer - Individual Markers by IHC Colorectal Cancer - Microsatellite Instability by PCR Colorectal Cancer - Profiles DNA Ploidy Analysis by Image Analysis DNA Ploidy/S-Phase Analysis by Flow Cytometry Drug Resistance Assay (DRA™) EGFR Amplification by FISH in NSCLC EGFR Mutation Analysis in NSCLC FIP1L1-PDGFRa Analysis in Hypereosinophilic Syndrome (HES) Disorders FISH (Fluorescence In Situ Hybridization) Flow Cytometry - interactiveFLOW Flow Cytometry, Six-Color (Immunophenotyping) Hematopathology Consultation Services HER2 by FISH (PathVysion) IgVH Mutation Analysis in B-CLL Immunohistochemistry (IHC) Immunohistochemistry (IHC) - Complex Tumor Analysis Immunohistochemistry (IHC) - Individual Markers Infectious Agents by Immunohistochemistry Infectious Agents by In Situ Hybridation Inv(16) RT-PCR JAK2 Mutation Analysis in Myeloproliferative Disorders KRAS Mutation Analysis Micrometastases - Bone Marrow/Peripheral Blood/Stem Cell Micrometastases - Melanoma/Carcinoma in Lymph Node Molar Pregnancy Evaluation (p57 and DNA Ploidy/S-Phase) Morphology – Special Stains p53 Mutation Analysis in B-CLL Pathology Consultation Services Peripheral Blood Smear Interpretation PML/RARA – t(15;17) by RT-PCR T-Cell Gene Rearrangements by PCR UGT1A1 Molecular Assay Urovysion™ by FISH